Fitzgerald Kevin Joseph, CSO and EVP Head of Research at Alnylam Pharmaceuticals ($ALNY), sold common shares on the open market eighty-six times over the last year, totaling $11.4 million. His most recent sale occurred on March 5, 2026. These sales rank him 1023rd among 11,678 insiders in our database by total value sold, above the average of $8.6 million across about 6.4 transactions per insider. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 5, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 124 | $321.81 | 21,640.0000 | 134,684,000 | 0.57% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 57 | $325.67 | 21,764.0000 | 134,684,000 | 0.26% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 75 | $324.88 | 21,821.0000 | 134,684,000 | 0.34% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 210 | $323.84 | 21,896.0000 | 134,684,000 | 0.95% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 96 | $323.01 | 22,106.0000 | 134,684,000 | 0.43% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 79 | $321.82 | 22,202.0000 | 134,684,000 | 0.35% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 59 | $320.81 | 22,281.0000 | 134,684,000 | 0.26% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 28 | $320.01 | 22,340.0000 | 134,684,000 | 0.13% | 0.00% |
| March 4, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 29 | $319.03 | 22,368.0000 | 134,684,000 | 0.13% | 0.00% |
| March 5, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 153 | $326.24 | 21,106.0000 | 134,684,000 | 0.72% | 0.00% |
| March 5, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 148 | $324.60 | 21,259.0000 | 134,684,000 | 0.69% | 0.00% |
| March 5, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 233 | $323.25 | 21,407.0000 | 134,684,000 | 1.08% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 392 | $326.81 | 24,860.0000 | 134,684,000 | 1.55% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 258 | $325.63 | 25,252.0000 | 134,684,000 | 1.01% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 90 | $324.65 | 25,510.0000 | 134,684,000 | 0.35% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 3688 | $0.00 | 25,647.0000 | 134,684,000 | 16.79% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 47 | $323.62 | 25,600.0000 | 134,684,000 | 0.18% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Stock Option (right to buy) | 8105 | $0.00 | 8,105.0000 | 134,684,000 | 9999.99% | 0.01% |
| March 3, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 359 | $321.58 | 22,397.0000 | 134,684,000 | 1.58% | 0.00% |
| March 3, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 722 | $320.51 | 22,756.0000 | 134,684,000 | 3.08% | 0.00% |
| March 3, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 282 | $318.62 | 23,478.0000 | 134,684,000 | 1.19% | 0.00% |
| March 3, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 289 | $316.55 | 23,760.0000 | 134,684,000 | 1.20% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 37 | $332.64 | 24,049.0000 | 134,684,000 | 0.15% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 94 | $331.93 | 24,086.0000 | 134,684,000 | 0.39% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 81 | $330.85 | 24,180.0000 | 134,684,000 | 0.33% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 170 | $329.71 | 24,261.0000 | 134,684,000 | 0.70% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 100 | $328.71 | 24,431.0000 | 134,684,000 | 0.41% | 0.00% |
| March 2, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 329 | $327.67 | 24,531.0000 | 134,684,000 | 1.32% | 0.00% |
| Feb. 26, 2026 | Ovid Therapeutics Inc. | $OVID | Fitzgerald Kevin Joseph | Not found | A | Employee Stock Option (Right to Buy) | 65000 | $0.00 | 65,000.0000 | 71,212,353 | 9999.99% | 0.09% |
| Feb. 23, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 158 | $0.00 | 21,959.0000 | 134,684,000 | 0.72% | 0.00% |
| Feb. 13, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 1959 | $310.08 | 23,842.0000 | 134,684,000 | 7.59% | 0.00% |
| Feb. 17, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 2041 | $331.96 | 21,801.0000 | 134,684,000 | 8.56% | 0.00% |
| Feb. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 4000 | $0.00 | 25,801.0000 | 134,684,000 | 18.35% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 92 | $368.62 | 24,200.0000 | 134,684,000 | 0.38% | 0.00% |
| Jan. 13, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 122 | $374.33 | 21,801.0000 | 134,684,000 | 0.56% | 0.00% |
| Jan. 13, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 280 | $372.93 | 21,923.0000 | 134,684,000 | 1.26% | 0.00% |
| Jan. 13, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 485 | $371.24 | 22,203.0000 | 134,684,000 | 2.14% | 0.00% |
| Jan. 13, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 644 | $370.00 | 22,688.0000 | 134,684,000 | 2.76% | 0.00% |
| Jan. 13, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 562 | $368.76 | 23,332.0000 | 134,684,000 | 2.35% | 0.00% |
| Jan. 13, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 197 | $367.52 | 23,894.0000 | 134,684,000 | 0.82% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 15 | $377.82 | 24,091.0000 | 134,684,000 | 0.06% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 19 | $375.65 | 24,106.0000 | 134,684,000 | 0.08% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 14 | $374.44 | 24,125.0000 | 134,684,000 | 0.06% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 2 | $372.46 | 24,139.0000 | 134,684,000 | 0.01% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 19 | $370.87 | 24,141.0000 | 134,684,000 | 0.08% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 40 | $369.48 | 24,160.0000 | 134,684,000 | 0.17% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 220 | $365.56 | 24,383.0000 | 134,684,000 | 0.89% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 199 | $364.83 | 24,603.0000 | 134,684,000 | 0.80% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 47 | $363.55 | 24,802.0000 | 134,684,000 | 0.19% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 73 | $362.38 | 24,849.0000 | 134,684,000 | 0.29% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 98 | $361.45 | 24,922.0000 | 134,684,000 | 0.39% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 155 | $360.22 | 25,020.0000 | 134,684,000 | 0.62% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 85 | $359.14 | 25,175.0000 | 134,684,000 | 0.34% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 123 | $358.18 | 25,260.0000 | 134,684,000 | 0.48% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 96 | $357.17 | 25,383.0000 | 134,684,000 | 0.38% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 41 | $356.09 | 25,479.0000 | 134,684,000 | 0.16% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 42 | $355.16 | 25,520.0000 | 134,684,000 | 0.16% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 39 | $353.95 | 25,562.0000 | 134,684,000 | 0.15% | 0.00% |
| Jan. 11, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 3800 | $0.00 | 25,601.0000 | 134,684,000 | 17.43% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 41 | $367.40 | 24,292.0000 | 134,684,000 | 0.17% | 0.00% |
| Jan. 12, 2026 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 50 | $366.41 | 24,333.0000 | 134,684,000 | 0.21% | 0.00% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | M | Common Stock | 8161 | $119.13 | 33,929.0000 | 137,348,000 | 31.67% | 0.01% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 129 | $451.51 | 25,536.0000 | 137,348,000 | 0.50% | 0.00% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 96 | $450.09 | 25,665.0000 | 137,348,000 | 0.37% | 0.00% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 8168 | $449.00 | 25,761.0000 | 137,348,000 | 24.07% | 0.01% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | M | Stock Option (right to buy) | 8161 | $0.00 | 839.0000 | 137,348,000 | 90.68% | 0.01% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 295 | $463.08 | 21,801.0000 | 137,348,000 | 1.34% | 0.00% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 323 | $461.96 | 22,096.0000 | 137,348,000 | 1.44% | 0.00% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 707 | $460.84 | 22,419.0000 | 137,348,000 | 3.06% | 0.00% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 622 | $459.89 | 23,126.0000 | 137,348,000 | 2.62% | 0.00% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 794 | $458.41 | 23,748.0000 | 137,348,000 | 3.24% | 0.00% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 262 | $457.39 | 24,542.0000 | 137,348,000 | 1.06% | 0.00% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 364 | $456.25 | 24,804.0000 | 137,348,000 | 1.45% | 0.00% |
| Nov. 17, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 368 | $455.24 | 25,168.0000 | 137,348,000 | 1.44% | 0.00% |
| Oct. 1, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 2102 | $0.00 | 25,358.0000 | 137,348,000 | 9.04% | 0.00% |
| Oct. 1, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 2851 | $0.00 | 28,209.0000 | 137,348,000 | 11.24% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 96 | $446.53 | 28,113.0000 | 137,348,000 | 0.34% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 47 | $447.92 | 28,066.0000 | 137,348,000 | 0.17% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 150 | $448.77 | 27,916.0000 | 137,348,000 | 0.53% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 207 | $449.79 | 27,709.0000 | 137,348,000 | 0.74% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 449 | $450.81 | 27,260.0000 | 137,348,000 | 1.62% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 276 | $451.86 | 26,984.0000 | 137,348,000 | 1.01% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 555 | $452.69 | 26,429.0000 | 137,348,000 | 2.06% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 273 | $453.77 | 26,156.0000 | 137,348,000 | 1.03% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 203 | $454.84 | 25,953.0000 | 137,348,000 | 0.78% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 60 | $455.82 | 25,893.0000 | 137,348,000 | 0.23% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 122 | $457.43 | 25,771.0000 | 137,348,000 | 0.47% | 0.00% |
| Oct. 2, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 3 | $457.64 | 25,768.0000 | 137,348,000 | 0.01% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 12 | $455.82 | 23,256.0000 | 127,651,000 | 0.05% | 0.00% |
| Aug. 15, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 2851 | $0.00 | 24,652.0000 | 127,651,000 | 13.08% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 241 | $454.84 | 23,268.0000 | 127,651,000 | 1.03% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 543 | $454.04 | 23,509.0000 | 127,651,000 | 2.26% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 329 | $452.96 | 24,052.0000 | 127,651,000 | 1.35% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 103 | $451.99 | 24,381.0000 | 127,651,000 | 0.42% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 39 | $450.92 | 24,484.0000 | 127,651,000 | 0.16% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 90 | $449.92 | 24,523.0000 | 127,651,000 | 0.37% | 0.00% |
| Aug. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 39 | $447.98 | 24,613.0000 | 127,651,000 | 0.16% | 0.00% |
| July 1, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 7763 | $0.00 | 21,801.0000 | 127,651,000 | 55.30% | 0.01% |
| Feb. 20, 2025 | Ovid Therapeutics Inc. | $OVID | Fitzgerald Kevin Joseph | Not found | A | Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| March 4, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 121 | $239.24 | 14,761.0000 | 127,651,000 | 0.81% | 0.00% |
| March 4, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 328 | $240.95 | 14,433.0000 | 127,651,000 | 2.22% | 0.00% |
| March 4, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 324 | $241.68 | 14,109.0000 | 127,651,000 | 2.24% | 0.00% |
| March 4, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 71 | $242.93 | 14,038.0000 | 127,651,000 | 0.50% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Stock Option (right to buy) | 7819 | $0.00 | 7,819.0000 | 127,651,000 | 9999.99% | 0.01% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 4 | $247.35 | 16,054.0000 | 127,651,000 | 0.02% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 151 | $244.41 | 16,214.0000 | 127,651,000 | 0.92% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 224 | $243.36 | 16,365.0000 | 127,651,000 | 1.35% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 204 | $242.37 | 16,589.0000 | 127,651,000 | 1.21% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 3871 | $0.00 | 16,793.0000 | 127,651,000 | 29.96% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 111 | $245.26 | 16,103.0000 | 127,651,000 | 0.68% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 45 | $246.18 | 16,058.0000 | 127,651,000 | 0.28% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 1 | $248.36 | 16,053.0000 | 127,651,000 | 0.01% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 465 | $242.69 | 15,588.0000 | 127,651,000 | 2.90% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 487 | $243.94 | 15,101.0000 | 127,651,000 | 3.12% | 0.00% |
| March 3, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 219 | $245.30 | 14,882.0000 | 127,651,000 | 1.45% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 27 | $236.51 | 13,391.0000 | 127,651,000 | 0.20% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 21 | $238.33 | 13,370.0000 | 127,651,000 | 0.16% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 22 | $239.18 | 13,348.0000 | 127,651,000 | 0.16% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 48 | $240.32 | 13,300.0000 | 127,651,000 | 0.36% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 79 | $241.51 | 13,221.0000 | 127,651,000 | 0.59% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 187 | $242.44 | 13,034.0000 | 127,651,000 | 1.41% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 75 | $243.23 | 12,959.0000 | 127,651,000 | 0.58% | 0.00% |
| Feb. 28, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 37 | $244.11 | 12,922.0000 | 127,651,000 | 0.29% | 0.00% |
| Feb. 13, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 2103 | $0.00 | 15,521.0000 | 127,651,000 | 15.67% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 83 | $259.10 | 13,418.0000 | 127,651,000 | 0.61% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 76 | $257.79 | 13,501.0000 | 127,651,000 | 0.56% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 80 | $256.05 | 13,577.0000 | 127,651,000 | 0.59% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 115 | $251.60 | 13,657.0000 | 127,651,000 | 0.84% | 0.00% |
| Feb. 18, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 1086 | $250.21 | 13,772.0000 | 127,651,000 | 7.31% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 14 | $264.87 | 14,858.0000 | 127,651,000 | 0.09% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 12 | $263.33 | 14,872.0000 | 127,651,000 | 0.08% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 26 | $261.45 | 14,884.0000 | 127,651,000 | 0.17% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 21 | $260.57 | 14,910.0000 | 127,651,000 | 0.14% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 12 | $259.72 | 14,931.0000 | 127,651,000 | 0.08% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 33 | $258.07 | 14,943.0000 | 127,651,000 | 0.22% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 26 | $257.51 | 14,976.0000 | 127,651,000 | 0.17% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 53 | $256.29 | 15,002.0000 | 127,651,000 | 0.35% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 47 | $255.56 | 15,055.0000 | 127,651,000 | 0.31% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 110 | $254.35 | 15,102.0000 | 127,651,000 | 0.72% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 164 | $253.37 | 15,212.0000 | 127,651,000 | 1.07% | 0.00% |
| Feb. 14, 2025 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 145 | $252.50 | 15,376.0000 | 127,651,000 | 0.93% | 0.00% |
| Dec. 12, 2024 | Ovid Therapeutics Inc. | $OVID | Fitzgerald Kevin Joseph | Not found | A | Stock Option (Right to Buy) | 90000 | $0.00 | 90,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 215 | $249.60 | 16,177.0000 | 128,590,000 | 1.31% | 0.00% |
| Nov. 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 318 | $250.68 | 15,859.0000 | 128,590,000 | 1.97% | 0.00% |
| Nov. 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 826 | $251.42 | 15,033.0000 | 128,590,000 | 5.21% | 0.00% |
| Nov. 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 84 | $252.27 | 14,949.0000 | 128,590,000 | 0.56% | 0.00% |
| Nov. 27, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 210 | $250.45 | 14,739.0000 | 128,590,000 | 1.40% | 0.00% |
| Nov. 27, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 851 | $251.98 | 13,888.0000 | 128,590,000 | 5.77% | 0.00% |
| Nov. 27, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 360 | $253.44 | 13,528.0000 | 128,590,000 | 2.59% | 0.00% |
| Nov. 27, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 110 | $254.48 | 13,418.0000 | 128,590,000 | 0.81% | 0.00% |
| Nov. 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 3000 | $0.00 | 16,418.0000 | 128,590,000 | 22.36% | 0.00% |
| Nov. 26, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 26 | $247.77 | 16,392.0000 | 128,590,000 | 0.16% | 0.00% |
| Aug. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 135 | $274.65 | 13,418.0000 | 124,906,000 | 1.00% | 0.00% |
| Aug. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | M | Common Stock | 6667 | $97.72 | 21,385.0000 | 124,906,000 | 45.30% | 0.01% |
| Aug. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | M | Common Stock | 14058 | $85.00 | 35,443.0000 | 124,906,000 | 65.74% | 0.01% |
| Aug. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 1421 | $268.66 | 34,022.0000 | 124,906,000 | 4.01% | 0.00% |
| Aug. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 9662 | $270.17 | 24,360.0000 | 124,906,000 | 28.40% | 0.01% |
| Aug. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 5736 | $271.32 | 18,624.0000 | 124,906,000 | 23.55% | 0.00% |
| Aug. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 3913 | $272.43 | 14,711.0000 | 124,906,000 | 21.01% | 0.00% |
| Aug. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 1158 | $273.73 | 13,553.0000 | 124,906,000 | 7.87% | 0.00% |
| Aug. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | M | Stock Option (right to buy) | 14058 | $0.00 | 2,192.0000 | 124,906,000 | 86.51% | 0.01% |
| Aug. 12, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | M | Stock Option (right to buy) | 6667 | $0.00 | 0.0000 | 124,906,000 | 100.00% | 0.01% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 125 | $235.19 | 14,718.0000 | 124,906,000 | 0.84% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 9 | $224.17 | 15,862.0000 | 124,906,000 | 0.06% | 0.00% |
| June 24, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | A | Common Stock | 2498 | $0.00 | 15,916.0000 | 124,906,000 | 18.62% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 45 | $221.71 | 15,871.0000 | 124,906,000 | 0.28% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 13 | $225.55 | 15,849.0000 | 124,906,000 | 0.08% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 26 | $226.82 | 15,823.0000 | 124,906,000 | 0.16% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 96 | $228.30 | 15,727.0000 | 124,906,000 | 0.61% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 198 | $229.06 | 15,529.0000 | 124,906,000 | 1.26% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 227 | $229.93 | 15,302.0000 | 124,906,000 | 1.46% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 74 | $231.59 | 15,228.0000 | 124,906,000 | 0.48% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 161 | $232.54 | 15,067.0000 | 124,906,000 | 1.06% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 86 | $233.53 | 14,981.0000 | 124,906,000 | 0.57% | 0.00% |
| June 25, 2024 | ALNYLAM PHARMACEUTICALS, INC. | $ALNY | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | S | Common Stock | 138 | $234.66 | 14,843.0000 | 124,906,000 | 0.92% | 0.00% |
| Feb. 22, 2024 | Ovid Therapeutics Inc. | $OVID | Fitzgerald Kevin Joseph | Director | A | Stock Option (Right to Buy) | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Ovid Therapeutics Inc. | $OVID | Fitzgerald Kevin Joseph | Director | A | Stock Option (Right to Buy) | 15000 | $0.00 | 15,000.0000 | 0 | 9999.99% | 0.00% |